Literature DB >> 8625223

Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma.

T Naka1, T Fukuda, N Shinohara, Y Iwamoto, Y Sugioka, M Tsuneyoshi.   

Abstract

BACKGROUND: It is often difficult to discriminate between osteosarcoma and malignant fibrous histiocytoma (MFH) of bone, especially in older patients because of the clinical similarities, including the lytic radiologic appearance. A histologic analysis of MFH-like osteosarcoma, which closely resembles MFH of bone both clinically and radiologically, has not yet been conducted thoroughly, and therefore this issue remains controversial.
METHODS: Using clinicopathologic and immunohistochemical techniques, the authors studied 24 cases of osteosarcoma arising in patients older than 40 years of age and compared them with 20 cases of MFH of bone from similarly aged patients.
RESULTS: Radiography revealed that 68.2% of the osteosarcoma cases were predominantly lytic, whereas all cases of MFH of bone showed either a predominantly or purely lytic pattern. Histologically, osteosarcoma was subclassified as conventional osteoblastic (54.2%), MFH-like (29.2%) containing various amounts of tumor osteoid and/or bone in each of the cases, and conventional fibroblastic (4.2%), whereas all the cases of MFH of bone had a storiform-pleomorphic pattern. Immunohistochemically, no overexpression of p53 protein was found in MFH-like osteosarcoma, whereas it tended to occur more frequently in osteoblastic osteosarcoma (66.7%) and MFH of bone (50.0%). The Ki-67 labeling index was significantly lower in MFH-like osteosarcoma than in MFH of bone. The 5-year survival rate was 18.2% in patients with osteoblastic osteosarcoma, 66.7% in patients with MFH-like osteosarcoma, and 21.5% in patients with MFH of bone. A significant difference in the survival curve was observed between osteoblastic and MFH-like osteosarcoma.
CONCLUSIONS: It is proposed that MFH-like osteosarcoma, which shows characteristically different clinical and histologic features from that of conventional osteosarcoma, thus may be considered a variant of osteosarcoma.

Entities:  

Mesh:

Year:  1995        PMID: 8625223     DOI: 10.1002/1097-0142(19950915)76:6<972::aid-cncr2820760610>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone.

Authors:  T Ueda; N Araki; M Mano; A Myoui; S Joyama; S Ishiguro; H Yamamura; K Takahashi; I Kudawara; H Yoshikawa
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

Review 2.  The rare primary bone sarcomas: imaging-pathological correlation.

Authors:  Rupert Berkeley; Vanghelita Andrei; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2021-01-07       Impact factor: 2.199

3.  MFH of bone and osteosarcoma show similar survival and chemosensitivity.

Authors:  Dae-Geun Jeon; Won Seok Song; Chang-Bae Kong; Jung Ryul Kim; Soo-Yong Lee
Journal:  Clin Orthop Relat Res       Date:  2010-06-18       Impact factor: 4.176

4.  Prognosis of Primary Osteosarcoma in Elderly Patients: A Comparison between Young and Elderly Patients.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Hiroyuki Nagasawa; Naohisa Miyakoshi; Yasutaka Murahashi; Junya Shimizu; Emi Mizushima; Toshihiko Yamashita; Yoichi Shimada
Journal:  Med Princ Pract       Date:  2019-04-17       Impact factor: 1.927

5.  The expression and significance of IDH1 and p53 in osteosarcoma.

Authors:  Xiang Hu; Ai-Xi Yu; Bai-Wen Qi; Tao Fu; Gang Wu; Min Zhou; Jun Luo; Jun-Hua Xu
Journal:  J Exp Clin Cancer Res       Date:  2010-05-07

6.  Primary osteosarcoma in patients older than 40 years of age.

Authors:  Dae Geun Jeon; Soo Yong Lee; Wan Hyung Cho; Won Seok Song; Jong Hoon Park
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

7.  Chemotherapy in primary osteogenic sarcoma in patients over the age of forty.

Authors:  Bulent Ozkurt; Kerem Basarir; Bulent Yalcin; Abdullah Merter; Yusuf Yildiz; Yener Saglik
Journal:  Acta Orthop Traumatol Turc       Date:  2017-02-16       Impact factor: 1.511

8.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25

9.  Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival?

Authors:  Eugene T H Ek; Joseline Ojaimi; Yasuyuki Kitagawa; Peter F M Choong
Journal:  Int Semin Surg Oncol       Date:  2006-03-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.